Orlando Ustariz-Gonzáles

  • Citations Per Year
Learn More
We report the use of intravitreal bevacizumab as a new option in the treatment of central serous chorioretinopathy (CSC). Five eyes with retinal pigment epithelium (RPE) leaks secondary to CSC received intravitreal bevacizumab (2.5 mg/0.1 cc), and underwent best corrected visual acuity, fluorescein angiography and optical coherent tomography before, 1, 3(More)
  • 1